GlassScriptPhysician profile
Antonio A Flores
NPI 1508853938
$7,089.48
in general payments reported to CMS, 2019-2025
48 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $531 · 2021: $1,100 · 2022: $1,090 · 2023: $1,356 · 2024: $1,178 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,552 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,551.59 |
| Education | $133.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $899.96 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $540.77 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $463.59 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $451.51 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $437.03 | 2021-2025 | Repatha, Otezla, Evenity |
| Astellas Pharma US INC | $381.61 | 2019-2023 | Myrbetriq |
| Amarin Pharma, INC. | $297.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $270.38 | 2019-2025 | |
| Alpha Cognition USA, INC. | $259.64 | 2025 | Zunveyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.15 | 2020-2022 | |
| Shield Therapeutics INC | $230.59 | 2023-2025 | Accrufer |
| Abbvie INC. | $214.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.25 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Kowa Pharmaceuticals America, INC. | $202.39 | 2019-2024 | Zoryve, Livalo, Seglentis |
| Glaxosmithkline, LLC. | $189.04 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.